These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20926010)

  • 1. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland.
    Basak GW; Drozd-Sokołowska J; Wiktor-Jedrzejczak W
    J Int Med Res; 2010; 38(4):1374-80. PubMed ID: 20926010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland.
    Maj S; Centkowski P
    Med Sci Monit; 2004 Sep; 10(9):PI93-5. PubMed ID: 15328493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of metamizole sodium-induced agranulocytosis in Poland.
    Maj S; Lis Y
    J Int Med Res; 2002; 30(5):488-95. PubMed ID: 12449518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).
    Hedenmalm K; Spigset O
    Eur J Clin Pharmacol; 2002 Jul; 58(4):265-74. PubMed ID: 12136373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study.
    Huber M; Andersohn F; Sarganas G; Bronder E; Klimpel A; Thomae M; Konzen C; Kreutz R; Garbe E
    Eur J Clin Pharmacol; 2015 Feb; 71(2):219-27. PubMed ID: 25378038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.
    Klose S; Pflock R; König IR; Linder R; Schwaninger M
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):681-690. PubMed ID: 31811328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports.
    Blaser LS; Tramonti A; Egger P; Haschke M; Krähenbühl S; Rätz Bravo AE
    Eur J Clin Pharmacol; 2015 Feb; 71(2):209-17. PubMed ID: 25401171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Agranulocytosis induced by metamizole and its management with granulocyte growth factor].
    Celeketić D; Trpković A; Cvetković Z
    Vojnosanit Pregl; 2005 Jan; 62(1):79-82. PubMed ID: 15715354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in EudraVigilance 1985-2017.
    Hoffmann F; Bantel C; Jobski K
    Basic Clin Pharmacol Toxicol; 2020 Feb; 126(2):116-125. PubMed ID: 31449718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis.
    Bäckström M; Hägg S; Mjörndal T; Dahlqvist R
    Pharmacoepidemiol Drug Saf; 2002; 11(3):239-45. PubMed ID: 12051124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012.
    Stammschulte T; Ludwig WD; Mühlbauer B; Bronder E; Gundert-Remy U
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1129-38. PubMed ID: 26169297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of metamizole as a risk factor in the occurrence of agranulocytosis].
    Vlakhov V; Bakracheva N; Popova L
    Vutr Boles; 1988; 27(2):80-5. PubMed ID: 3046147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical otorhinolaryngological symptoms of metamizole-induced agranulocytosis].
    Send T; Westermann S; Eichhorn KW; Jakob M
    HNO; 2015 Mar; 63(3):215-9. PubMed ID: 25515122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Agranulocytosis and septic shock after metamizole use].
    Oude Munnik TH; Annink-Smoors M; Hom HW; Sportel ET
    Ned Tijdschr Geneeskd; 2016; 160():A9464. PubMed ID: 26840935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Agranulocytosis and metamizole].
    Hoerder U; König HJ; Hartwich G
    Dtsch Med Wochenschr; 1982 Dec; 107(50):1923-6. PubMed ID: 7140576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who gets dipyrone (metamizole) in Germany? Prescribing by age, sex and region.
    Hoffmann F; Meinecke P; Freitag MH; Glaeske G; Schulze J; Schmiemann G
    J Clin Pharm Ther; 2015 Jun; 40(3):285-8. PubMed ID: 25776531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metamizole use during first trimester-A prospective observational cohort study on pregnancy outcome.
    Dathe K; Padberg S; Hultzsch S; Meixner K; Tissen-Diabaté T; Meister R; Beck E; Schaefer C
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1197-1204. PubMed ID: 28771890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of metamizole: a systematic review of the literature.
    Andrade S; Bartels DB; Lange R; Sandford L; Gurwitz J
    J Clin Pharm Ther; 2016 Oct; 41(5):459-77. PubMed ID: 27422768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dipyrone (metamizole) : Considerations on monitoring for early detection of agranulocytosis].
    Stamer UM; Gundert-Remy U; Biermann E; Erlenwein J; Meiβner W; Wirz S; Stammschulte T
    Schmerz; 2017 Feb; 31(1):5-13. PubMed ID: 27766404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metamizole (Dipyrone) and the Liver: A Review of the Literature.
    Lutz M
    J Clin Pharmacol; 2019 Nov; 59(11):1433-1442. PubMed ID: 31433499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.